ACOG

Urogen Pharma reported a quarterly loss of $0.03 per share, beating the consensus estimate of $0.05, with revenues of $89 million exceeding expectations by 2.73%. Despite the positive earnings surprise and 46.9% year-to-date stock gain, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release, suggesting near-term underperformance relative to the market.

Alpha Teknova (TKNO) shares rose 5.1% to $6.15 after announcing robust preliminary Q3 2026 financial results with revenues expected between $12.5-$12.7 million. Despite the rally, the stock remains down 34.5% over the past four weeks.

The company is expected to post a quarterly loss of $0.06 per share with revenues up 12% year-over-year. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the recent jump may lack sustained momentum.